Otsuka And Lundbeck Announce U.S. FDA Approval Of Supplemental New Drug Application For Rexulti® (Brexpiprazole) For The Treatment Of Agitation Associated With Dementia Due To Alzheimer’s Disease

H Lundbeck A/S

11/05/2023 03:48

May 11 (Reuters) - Otsuka Holdings Co Ltd  4578.T :
    * OTSUKA HOLDINGS CO LTD - OTSUKA AND LUNDBECK ANNOUNCE U.S.
FDA
APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR REXULTI®
(BREXPIPRAZOLE) FOR THE TREATMENT OF AGITATION ASSOCIATED WITH
DEMENTIA DUE TO ALZHEIMER’S DISEASE

Source text for Eikon:  ID:nTSqk8a098 
Further company coverage:  4578.T 

 (Reporting by Eimi Yamamitsu)
 ((Eimi.Yamamitsu@thomsonreuters.com;))